I-BET762
-
- 应用范围
- Inhibition (Inh)
- 原理
- BET Bromodomain inhibitor, Suppresses Myc transcription
- 产品特性
- I-BET762 is a potent inhibitor of the BET family of bromodomains with no activity at bromodomains BAZ2B, SP140, ATAD2, CREBBO, and PCAF. IC50's for H4Ac peptide displacement: BRD2 = 32.5nM, BRD3 = 42.4nM, BRD4 = 36.1nM. It was able to suppress proinflammatory proteins by macrophage, block acute inflammation in mice, and suppressed the inflammatory function of T cells. Inhibition of BET bromodomains results in downregulation of Myc transcription, an important oncogene.
- 纯度
- >98 %
- Chemical Name
- (4S)- 6-(4-Chlorophenyl)-N-ethyl-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide
- Formula
- C22H22ClN5O2
- Solubility
- Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to at least 25 mg/ml)
-
Geldanamycin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
RadicicolInh 12772-57-5
Geldanamycin- FITCInh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
ResveratrolAct 501-36-0 3,4',5-Trihydroxy-trans-stilbene
PanobinostatInh 404950-80-7 (E)-N-Hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide
HPA (Hexyl-4-pentynoic acid)Inh Cell-permeable 96017-59-3 2-(2-Propynyl)octanoic acid (racemic)
EX-527Inh Cell-permeable 49843-98-3 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-xarboxamide (racemic)
DaminozideInh 1596-84-5 1-(2,2-Dimethylhydrazide)butanedioic acid
Mithramycin AInh 18378-89-7
PiceatannolInh 10083-24-6 3,3',4,5'-Tetrahydroxy-trans-stilbene
-
- 限制
- 仅限研究用
-
- 状态
- Powder
- 注意事项
-
GHS – Classification
Not a hazardous substance or mixture - 储存条件
- -20 °C
-
- 背景
- GSK525762,Epigenetics,Bromodomain,Immunology,Inflammation,Cancer,Posttranslational modification,Chromatin
- 分子量
- 423.90
- CAS-编号
- 1260907-17-2
-
